Activist investor Starboard is backing down in its fight at Pfizer after seeing little chance of winning board seats or rousing enough shareholder pressure to force out its CEO. A deadline to ...

Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan. Pfizer's ex-chair and chief executive Ian ...

Pfizer (PFE) CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the investor disclosed a stake in the company and ...

That drug came through Pfizer’s 2022 acquisition of Global Blood Therapeutics for US$5.4bil, one of a string of purchases that Starboard considers to have delivered poor results, the person said.

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

The American hedge fund Starboard Value has acquired a stake in Pfizer Inc. worth $1 billion. This is reported in the Starboard Value press release. Starboard Value is committed to accelerating the ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

That Pfizer’s turnaround is already well underway is reflected by the fact that activist investor Starboard Value, led by Jeffrey Smith, wisely chose not to nominate any dissident directors to ...